Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1147-1158

  Gertz, Michael ^a   Harrison, Anthony ^b   Houston, J Brian ^a   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ATORVASTATIN; BUSPIRONE; CISAPRIDE; CYCLOSPORIN; FELODIPINE; INDINAVIR; METHADONE; METOPROLOL; MEVINOLIN; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; NADOLOL; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; REPAGLINIDE; RIFABUTIN; SAQUINAVIR; SILDENAFIL; SIMVASTATIN; TACROLIMUS; TALINOLOL; TERFENADINE; TRAZODONE; VERAPAMIL; ZOLPIDEM; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A; DRUG;

ACCURACY; ACIDITY; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DOG; DONOR; DRUG CLEARANCE; DRUG PENETRATION; ENZYME SUBSTRATE; FIRST PASS EFFECT; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; KIDNEY CELL; LIVER MICROSOME; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; CACO 2 CELL LINE; ENZYMOLOGY; EVALUATION STUDY; FORECASTING; INTESTINE ABSORPTION; METABOLIC CLEARANCE RATE; METABOLISM; MICROSOME; PROCEDURES; TRANSFORMED CELL LINE;

ANIMALS; CACO-2 CELLS; CELL LINE, TRANSFORMED; CYTOCHROME P-450 CYP3A; DOGS; FORECASTING; HUMANS; IN VITRO TECHNIQUES; INTESTINAL ABSORPTION; INTESTINES; METABOLIC CLEARANCE RATE; MICROSOMES; MICROSOMES, LIVER; MIDAZOLAM; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHYSICOCHEMICAL PHENOMENA;

EID: 77953737073     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032649     Document Type: Article

References (49)

1. Badhan R, Penny J, Galetin A, and Houston JB (2009) Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J Pharm Sci 98:2180-2197.
2. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45.
3. Chalasani N, Gorski JC, Patel NH, Hall SD, and Galinsky RE (2002) Reply to Rostami-Hodjegan and Tucker 2002; Hepatology 35(5): 1549-1550.
4. Hepatology 35:1550-1551.
5. Chiba M, Hensleigh M, and Lin JH (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol 53:1187-1195.
6. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
7. Ernest CS 2nd, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591.
8. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
9. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, and Rasmussen HH (1989) pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 3:605-613. (Pubitemid 20118814)
10. Galetin A, Brown C, Hallifax D, Ito K, and Houston JB (2004) Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab Dispos 32:1411-1420.
11. Galetin A, Clarke SE, and Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 31:1108-1116.
12. Galetin A, Gertz M, and Houston JB (2008) Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 4:909-922.
13. Galetin A, Gertz M, and Houston JB (2010) Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 25:28-47.
14. Galetin A and Houston JB (2006) Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318: 1220-1229.
15. Gertz M, Davis JD, Harrison A, Houston JB, and Galetin A (2008a) Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 9:785-795.
16. Gertz M, Kilford PJ, Houston JB, and Galetin A (2008b) Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535-542. (Pubitemid 351397979)
17. Granger DN, Richardson PD, Kvietys PR, and Mortillaro NA (1980) Intestinal blood flow. Gastroenterology 78:837-863.
18. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, et al. (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161-166.
19. Hallifax D and Houston JB (2006) Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724-727.
20. Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, and Prueksaritanont T (2004) Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 21:1686-1691. (Pubitemid 41184401)
21. Huang W, Lin YS, McConn DJ 2nd, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
22. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112.
23. Ito K, Kusuhara H, and Sugiyama Y (1999) Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm Res 16:225-231. (Pubitemid 29135126)
24. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, and Tucker G (2009) Population-based mechanistic prediction of oral drug absorption. AAPS J 11:225-237.
25. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, et al. (2003) The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365-372.
26. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552-561.
27. Lennernäs H (2007) Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37:1015-1051.
28. Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
29. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037.
30. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
31. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
32. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562. (Pubitemid 28016533)
33. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
34. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628. (Pubitemid 32979675)
35. Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
36. Rostami-Hodjegan A and Tucker GT (2002) The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology 35:1549-1550.
37. Rostami-Hodjegan A and Tucker G (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today 1:441.
38. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
39. Rowland-Yeo, Rostami-Hodjegan A, and Tucker GT (2004) Abundance of cytochrome P450 in human liver: a meta-analysis. Br J Clin Pharmacol 57:687-688.
40. Sheiner LB and Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512.
41. Strassburg CP, Barut A, Obermayer-Straub P, Li Q, Nguyen N, Tukey RH, and Manns MP (2001) Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. J Hepatol 34:865-872.
42. Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, and Amidon GL (2002) Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 19:1400-1416.
43. Tam D, Sun H, and Pang KS (2003) Influence of P-glycoprotein, transfer clearances, and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis. Drug Metab Dispos 31:1214-1226.
44. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, and Wood AJ (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59: 3944-3948. (Pubitemid 29393559)
45. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266.
46. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernäs H, and Karlén A (1998) Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 41:4939-4949.
47. Wu X, Whitfield LR, and Stewart BH (2000) Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 17:209-215.
48. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2007) Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
49. Yeh KC, Stone JA, Carides AD, Rolan P, Woolf E, and Ju WD (1999) Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. J Pharm Sci 88:568-573.